Taymeyah Al-Toubah, MPH, is the Senior Clinical Research Coordinator at Moffitt Cancer Center in Tampa, Florida. She will be the featured guest for CCF’s Facebook Live Luncheon with the Experts on Thursday, May 19, 2022 from 12 noon to 1 pm, Eastern Time. Ms. Al-Toubah leads the GI research program at Moffitt, while managing all of the neuroendocrine tumor (NET) clinical trials.
Ms. Al-Toubah’s educational background is in biomedical sciences, psychology, and public health. She has been working in clinical research since 2013, and has been in oncology since 2016, exclusively in NET since 2018. She is involved in all aspects of NET clinical trials including screening, enrolling and monitoring trial participants throughout the life cycle of their trial; serving as a liaison between patients and all providers; and actively protecting and assuring the safety of patients on research protocols.
Among the clinical trials in which she is currently involved are:
- The CABINET trial, Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- The COMPOSE trial, Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – COMPOSE, this trial just opened at Moffitt
- The AlphaMedix trial, Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02), this trial just opened at Moffitt
- Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract (a non-treatment trial, this offers an opportunity for patients with poorly differentiated neuroendocrine carcinoma to get a Gallium 68 PET/CT scan but only at Moffitt)
Click here for a list of Ms. Al-Toubah’s publications, including:
- “Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors,” “Chemotherapy in Neuroendocrine Tumors”
- “Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ?10%?”
- “Chemotherapy in Neuroendocrine Tumors”
- “Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms”
- “Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide”
Read more about the Neuroendocrine Tumor Program at the Moffitt Cancer Center here: https://moffitt.org/cancers/neuroendocrine-tumor/.
CCF’s Luncheon with the Experts series features physicians and healthcare professionals, support group leaders, patients, and colleagues who are key opinion leaders in the neuroendocrine cancer community worldwide. This weekly series is presented via Facebook Live on Thursdays from 12 noon to 1 pm, Eastern Time. Join us for unique discussions on a wide variety of topics for everyone in the NET community!
To view the program come to CCF’s Facebook page, https://www.facebook.com/Carcinoid/, at noon Eastern Time. There is no need to register and there is no special link.
Viewers are welcome to pose questions during the live program.
The Facebook Live events are hosted by B. Rain Bennett, a longtime CCF filmmaker and dear friend of the NETs community.
If you are on Facebook but unable to join at the scheduled time, the presentations will remain permanently on CCF’s Facebook page in the Video section, https://www.facebook.com/pg/Carcinoid/videos/. You can view all of the 2020-2022 presentations at that link too.
And for anyone not on Facebook, each of the presentations in the series is available on CCF’s YouTube channel, https://www.youtube.com/user/CarcinoidNETs. To receive notifications of all new videos on our YouTube channel, CLICK LIKE, SUBSCRIBE, and HIT THE BELL to receive notifications each time a new video is uploaded.
With special thanks to Ipsen Biopharmaceuticals, sponsor of the Luncheon with the Experts series.
Sign up for our e-newsletter to receive notifications about all upcoming Luncheon with the Experts programs, every Thursday from noon to 1 pm ET, as well as lots of additional news of interest to the NET community: https://bit.ly/SignUpCCFe-news.